Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | CDK4 | P11802 | 4/20 | 0.33 |
| ▸ | CCND1 | P24385 | 4/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 2/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4502403 | 0.84 | ALDH1A1 (0.48) | IDO1ALDH1A1CYP1A1CYP1A2CYP3A4 | |
| SCHEMBL15263672 | 0.77 | PAX8 (0.39) | IDO1ALDH1A1CYP1A2PARP1CYP2A6 | |
| SCHEMBL16523549 | 0.69 | — | — | |
| SCHEMBL25045527 | 0.64 | — | — | |
| SCHEMBL24701710 | 0.63 | ADRA2A (0.39) | ALDH1A1CYP1A2TSHRCYP2A6 | |
| SCHEMBL15984630 | 0.61 | ALDH1A1 (0.40) | ALDH1A1CYP1A1CYP1A2CYP3A4HPGD | |
| SCHEMBL25044247 | 0.57 | ALOX15 (0.36) | — | |
| Naphthalene SCHEMBL1331142 | 0.53 | CYP2A6 (1.00) | ALDH1A1CYP1A1CYP1A2CYP3A4HPGD | |
| Naphthalene SCHEMBL1330659 | 0.53 | CYP2A6 (1.00) | ALDH1A1CYP1A1CYP1A2CYP3A4HPGD | |
| Naphthalene SCHEMBL1332240 | 0.53 | CYP2A6 (1.00) | ALDH1A1CYP1A1CYP1A2CYP3A4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1348454-A | Tetracyclic azepinoindole compounds as 5-HT receptor ligands | UPJOHN CO (US) | 2002-05-08 | — | — | CN | claimed |
| EP-0145591-B1 | PYRROLO(3,2,1-HI)INDOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTICAL USE | SYNTHELABO (FR) | 1988-06-22 | — | — | EP | claimed |
| US-11697653-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2023-07-11 | — | — | US | disclosed |
| US-20070105908-A1 | Thiazolimine compound and oxazolimine compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| CN-1768745-A | Medicine for improving excretion capacity of bladder | TAKEDA PHARMACEUTICAL (JP) | 2006-05-10 | — | — | CN | disclosed |
| EP-1640369-A1 | THIAZOLIMINE COMPOUND AND OXAZOLIMINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-03-29 | — | — | EP | disclosed |
| US-6867198-B2 | Agents and methods for the treatment of proliferative diseases | ELI LILLY AND COMPANY (US) | 2005-03-15 | — | — | US | disclosed |
| CN-1589153-A | Prevention or treatment of urinary disorders | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2005-03-02 | — | — | CN | disclosed |
| CN-1572299-A | Medicine for improving excretion capacity of bladder | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2005-02-02 | — | — | CN | disclosed |
| EP-1500643-A1 | BENZAMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-01-26 | — | — | EP | disclosed |
| CN-1183132-C | Tetracyclic azepinoindole compounds as 5-HT receptor ligands | �������Ŷ���Լ��������˾ | 2005-01-05 | — | — | CN | disclosed |
| CN-1348454-A | Tetracyclic azepinoindole compounds as 5-HT receptor ligands | UPJOHN CO (US) | 2002-05-08 | — | — | CN | disclosed |
| CN-1328451-A | Medicine for improving excretion capacity of bladder | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-12-26 | — | — | CN | disclosed |
| EP-0311467-B1 | Use of pyrrolo[3,2,1-hi]indole derivatives in the manufacture of a medicament for the treatment of diabetes | SYNTHELABO (FR) | 1993-08-04 | — | — | EP | disclosed |
| EP-0311467-A2 | Use of pyrrolo[3,2,1-hi]indole derivatives in the manufacture of a medicament for the treatment of diabetes | SYNTHELABO (FR) | 1989-04-12 | — | — | EP | disclosed |
| EP-0311467-A2 | Use of pyrrolo[3,2,1-hi]indole derivatives in the manufacture of a medicament for the treatment of diabetes | SYNTHELABO (FR) | 1989-04-12 | — | — | EP | disclosed |
| EP-0145591-B1 | PYRROLO(3,2,1-HI)INDOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTICAL USE | SYNTHELABO (FR) | 1988-06-22 | — | — | EP | disclosed |
| US-4617313-A | ANTIDEPRESSANTS | SYNTHELABO (FR) | 1986-10-14 | — | — | US | disclosed |
| US-4617313-A | ANTIDEPRESSANTS | SYNTHELABO (FR) | 1986-10-14 | — | — | US | disclosed |
| EP-0145591-A2 | Pyrrolo(3,2,1-hi)indole derivatives, their preparation and their therapeutical use | SYNTHELABO (FR) | 1985-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11697653-B2 | Organic electroluminescent materials and devices | L1CAM, SOD1, EPCAM | IDO1 3966/4885ALDH1A1 380/4885CYP1A1 1562/4885 |
| US-20070105908-A1 | Thiazolimine compound and oxazolimine compound | CMA1, TH, NPR3 | IDO1 117/4885ALDH1A1 1307/4885CYP1A1 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.